Literature DB >> 20013806

Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.

Sara Michel1, Michael Linnebacher, Joshua Alcaniz, Maike Voss, Rudolf Wagner, Wolfgang Dippold, Christina Becker, Magnus von Knebel Doeberitz, Soldano Ferrone, Matthias Kloor.   

Abstract

Colorectal cancers (CRCs) develop on the basis of a deficient DNA mismatch repair (MMR) system in about 15% of cases. MMR-deficient CRC lesions show high-level microsatellite instability (MSI-H) and accumulate numerous mutations located at coding microsatellite loci that lead to the generation of immunogenic neopeptides. Consequently, the host's antitumoral immune response is of high importance for the course of the disease in MSI-H CRC patients. Accordingly, immune evasion mediated by impairment of HLA class I antigen presentation is frequently observed in these cancers. In this study, we aimed at a systematic analysis of alterations affecting HLA class II antigen expression in MSI-H CRC. HLA class II antigens are expressed by only two-thirds of MSI-H CRCs. The mechanisms underlying the lack of HLA class II antigens in a subset of MSI-H CRCs remain unknown. We here screened HLA class II regulatory genes for the presence of coding microsatellites and identified mutations of the essential regulator genes RFX5 in 9 (26.9%) out of 34 and CIITA in 1 (2.9%) out of 34 MSI-H CRCs. RFX5 mutations were related to lack of or faint HLA class II antigen expression (p = 0.006, Fisher's exact test). Transfection with wild-type RFX5 was sufficient to restore interferon gamma-inducible HLA class II antigen expression in the RFX5-mutant cell line HDC108. We conclude that somatic mutations of the RFX5 gene represent a novel mechanism of loss of HLA class II antigen expression in tumor cells, potentially contributing to immune evasion in MSI-H CRCs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013806      PMCID: PMC2892639          DOI: 10.1002/ijc.25106

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

Review 1.  Epigenetic silencing of MHC2TA transcription in cancer.

Authors:  Tjadine M Holling; Marja C J A van Eggermond; Martine J Jager; Peter J van den Elsen
Journal:  Biochem Pharmacol       Date:  2006-08-01       Impact factor: 5.858

2.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

Review 3.  Microsatellite instability in the development of DNA mismatch repair deficient tumors.

Authors:  Stefan M Woerner; Matthias Kloor; Magnus von Knebel Doeberitz; Johannes F Gebert
Journal:  Cancer Biomark       Date:  2006       Impact factor: 4.388

4.  Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).

Authors:  V Steimle; L A Otten; M Zufferey; B Mach
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

5.  Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.

Authors:  M Meissner; T L Whiteside; P van Kuik-Romein; E M Valesky; P J van den Elsen; R Kaufmann; B Seliger
Journal:  Br J Dermatol       Date:  2008-02-16       Impact factor: 9.302

6.  The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers.

Authors:  Stefan M Woerner; Matthias Kloor; Yvette Schwitalle; Hanni Youmans; Magnus von Knebel Doeberitz; Johannes Gebert; Susanne Dihlmann
Journal:  Genes Chromosomes Cancer       Date:  2007-12       Impact factor: 5.006

7.  A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.

Authors:  Tjadine M Holling; Marloes W T Bergevoet; Louis Wilson; Marja C J A Van Eggermond; Erik Schooten; Renske D M Steenbergen; Peter J F Snijders; Martine J Jager; Peter J Van den Elsen
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

8.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

9.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.

Authors:  Y Ionov; M A Peinado; S Malkhosyan; D Shibata; M Perucho
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

10.  A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome).

Authors:  V Steimle; B Durand; E Barras; M Zufferey; M R Hadam; B Mach; W Reith
Journal:  Genes Dev       Date:  1995-05-01       Impact factor: 11.361

View more
  26 in total

1.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.

Authors:  Jonas Janikovits; Meike Müller; Julia Krzykalla; Sandrina Körner; Fabian Echterdiek; Bernd Lahrmann; Niels Grabe; Martin Schneider; Axel Benner; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

2.  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.

Authors:  Fabian Echterdiek; Jonas Janikovits; Laura Staffa; Meike Müller; Bernd Lahrmann; Monika Frühschütz; Benjamin Hartog; Nina Nelius; Axel Benner; Mirjam Tariverdian; Magnus von Knebel Doeberitz; Niels Grabe; Matthias Kloor
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

3.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 4.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 5.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

6.  Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors.

Authors:  Elez D Vainer; Juliane Kania-Almog; Ghadeer Zatara; Yishai Levin; Gilad W Vainer
Journal:  Mol Cell Proteomics       Date:  2020-07-08       Impact factor: 5.911

Review 7.  Interplay between DNA repair and inflammation, and the link to cancer.

Authors:  Dawit Kidane; Wook Jin Chae; Jennifer Czochor; Kristin A Eckert; Peter M Glazer; Alfred L M Bothwell; Joann B Sweasy
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-01-13       Impact factor: 8.250

8.  Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Authors:  Catherine S Grasso; Marios Giannakis; Daniel K Wells; Tsuyoshi Hamada; Xinmeng Jasmine Mu; Michael Quist; Jonathan A Nowak; Reiko Nishihara; Zhi Rong Qian; Kentaro Inamura; Teppei Morikawa; Katsuhiko Nosho; Gabriel Abril-Rodriguez; Charles Connolly; Helena Escuin-Ordinas; Milan S Geybels; William M Grady; Li Hsu; Siwen Hu-Lieskovan; Jeroen R Huyghe; Yeon Joo Kim; Paige Krystofinski; Mark D M Leiserson; Dennis J Montoya; Brian B Nadel; Matteo Pellegrini; Colin C Pritchard; Cristina Puig-Saus; Elleanor H Quist; Ben J Raphael; Stephen J Salipante; Daniel Sanghoon Shin; Eve Shinbrot; Brian Shirts; Sachet Shukla; Janet L Stanford; Wei Sun; Jennifer Tsoi; Alexander Upfill-Brown; David A Wheeler; Catherine J Wu; Ming Yu; Syed H Zaidi; Jesse M Zaretsky; Stacey B Gabriel; Eric S Lander; Levi A Garraway; Thomas J Hudson; Charles S Fuchs; Antoni Ribas; Shuji Ogino; Ulrike Peters
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

Review 9.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

Review 10.  [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options].

Authors:  M Kloor
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.